Kintor Pharmaceutical Ltd (HK:9939) has released an update.
Kintor Pharmaceutical Ltd has announced the successful enrollment of the first participant in their Phase II clinical trial in China for GT20029, a novel acne treatment. GT20029, developed by Kintor’s in-house platform, is a topical androgen receptor targeting compound and marks a global first in reaching this stage of clinical testing. The trial is a multi-center, double-blind study aimed at evaluating the compound’s efficacy and safety, building on prior positive Phase I results for both acne and androgenetic alopecia.
For further insights into HK:9939 stock, check out TipRanks’ Stock Analysis page.
